Selecting an attorney for legal cases is a very important decision. Please enter your information below to receive a Free Consultation from an attorney in your area:
Drug Litigation News
SEC Files Disclosure Fraud Case Against Elan Corporation
Company Agrees To Settle Charges And Pay A $15 Million Penalty The Securities and Exchange Commission today announced the filing of a settled civil action against Elan Corporation, plc, a pharmaceutical company headquartered in Dublin, Ireland. The Commission charged Elan with violating the antifraud provisions of the federal securities laws for failing to disclose material information about the company's financial results in periodic reports filed with the Commission and in quarterly earnings press releases disseminated to investors in the United States.
According to the complaint, during 2000 and 2001, Elan represented in its public statements that it was generating record amounts of revenue, net income and operating cash flow from drug sales and licensing activities. Elan also claimed that it was making significant progress towards achieving its goal of transforming itself into a fully integrated pharmaceutical company and generating $5 billion of annual revenue by 2005. The complaint alleges that these statements were materially misleading because Elan failed to disclose, or inadequately disclosed, certain transactions that were critical to Elan's perceived success. As a result, investors were led to believe that Elan had achieved record results through improvements in the company's business, when in fact it had not.
Without admitting or denying the allegations in the complaint, Elan consented to the entry of a final judgment that permanently enjoins the company from violating the antifraud provisions of the federal securities laws, Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, as well as the reporting and internal controls provisions, Sections 13(a) and 13(b)(2)(B) of the Exchange Act and Rules 12b 20, 13a 1 and 13a 16 thereunder. The judgment also orders Elan to pay $1 in disgorgement and a $15 million civil penalty, which is intended to be distributed to investors harmed by the alleged violations. The final judgment is subject to Court approval.
Drug companies spend more on marketing than R&D
The top 10 drug companies spent nearly three times more on marketing, public relations and administration than they did on research and development.
Newsroom
News about Drug Litigation cases in Indiana and nationwide:
Pending Generic Drug Applications
If a patent is listed in the "Orange Book," an applicant seeking approval for an ANDA must submit a certification to the patent. Even an applicant ... Read more >
Definition:
A dosage form is the physical form in which a drug is produced and dispensed, such as a tablet, a capsule, or an injectable.
Label
Definition:
The FDA approved label is the official description of a drug product which includes indication (what the drug is used for); who should take it; adverse events (side effects); instructions for uses in pregnancy, children, and other populations; and safety
Review
Definition:
A review is the basis of FDA's decision to approve a new drug application.
Legal Disclaimers All attorney listings are a paid attorney advertisement, and do not in any way constitute a referral or endorsement by an approved or authorized lawyer referral service. The information provided on Indiana Drug Litigation.com is not intended to be legal advice, but merely conveys
general information related to legal issues commonly encountered. Your access
to and use of this website is subject to additional Terms
and Conditions.
Local Professional? Generate new business today
Call 866-227-9356 or contact a sales rep
Did You Know?